Drug intelligence / Profile preview

PTX-206

Development stage: Preclinical
Lead developer: Providence Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PTX-206 is an mRNA-based vaccine candidate being developed by Providence Therapeutics for the prevention of Salmonella infection. The vaccine utilizes a multiantigen approach, employing mRNA to encode several Salmonella-specific antigens designed to elicit a broad and protective immune response. By leveraging the host's cellular machinery to produce these bacterial antigens, PTX-206 aims to stimulate both humoral and cellular immunity to protect against Salmonella-induced disease. As of early 2024, the program is in the discovery stage of development.

Beyond the preview

Go deeper on PTX-206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTX-206.

Explore the full profile